verapamil has been researched along with Cancer of Ovary in 60 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We determined the cytotoxicity of methotrexate and the lipid-soluble antifolate trimetrexate to various human carcinoma cells and their doxorubicin-resistant sublines." | 7.67 | Cross-resistance to the lipid-soluble antifolate trimetrexate in human carcinoma cells with the multidrug-resistant phenotype. ( Assaraf, YG; Molina, A; Schimke, RT, 1989) |
| " We determined the cytotoxicity of methotrexate and the lipid-soluble antifolate trimetrexate to various human carcinoma cells and their doxorubicin-resistant sublines." | 3.67 | Cross-resistance to the lipid-soluble antifolate trimetrexate in human carcinoma cells with the multidrug-resistant phenotype. ( Assaraf, YG; Molina, A; Schimke, RT, 1989) |
| "Human ovarian cancer cell lines from drug resistant patients also has been demonstrated to increase levels of glutathione." | 2.37 | Multidrug resistance in ovarian cancer. ( Fojo, A; Hamilton, TC; Ozols, RF; Young, RC, 1987) |
| "Ovarian cancer is usually treated with transurethral resection or systemic chemotherapy in clinic." | 1.48 | Encapsulation of verapamil and doxorubicin by MPEG-PLA to reverse drug resistance in ovarian cancer. ( Li, M; Lin, Y; Zhan, X; Zheng, W, 2018) |
| "Clinical response to chemotherapy for ovarian cancer is frequently compromised by the development of drug-resistant disease." | 1.43 | ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells. ( Bray, SE; Chakravarty, P; Ferguson, MJ; Gannon, AL; Sawers, L; Scott, AL; Smith, G; Vaidyanathan, A, 2016) |
| "Our data suggest that ovarian cancer contain small sub-population of side population cells which shares some characteristics of stem cells." | 1.42 | Tumor recurrence and drug resistance properties of side population cells in high grade ovary cancer. ( Dou, HT; Liu, PS; Xu, P; Zhang, QH; Zhuang, SC, 2015) |
| "Verapamil was also inhibitory, indicating that gonadotropins activate calcium influx via L-type voltage-dependent calcium channels." | 1.36 | Gonadotropin-induced ovarian cancer cell migration and proliferation require extracellular signal-regulated kinase 1/2 activation regulated by calcium and protein kinase C{delta}. ( Baxter, RC; Bolitho, C; Marsh, DJ; Mertens-Walker, I, 2010) |
| "Verapamil treatment did not reverse the intrinsic drug resistance of parental cells, but partially modulated the sensitivity of CABA-PTX cells to PTX and induced total sensitivity to vinblastine." | 1.32 | Induction of a multifactorial resistance phenotype by high paclitaxel selective pressure in a human ovarian carcinoma cell line. ( Canevari, S; D'Ascenzo, S; Dolo, V; Millimaggi, D; Miotti, S; Pavan, A; Violini, S, 2004) |
| "D-Verapamil was only about half as toxic as racemic verapamil and this too is consistent with clinical observations." | 1.29 | Identification of a multidrug resistance modulator with clinical potential by analysis of synergistic activity in vitro, toxicity in vivo and growth delay in a solid human tumour xenograft. ( Bicknell, SR; Hamilton, T; Kaye, SB; Morrison, JG; Plumb, JA; Setanoians, A; Wishart, GC, 1994) |
| "Human ovarian cancer cell line SKOV3 was grown during a period of four months in the presence of increasing concentrations of cisplatin (25-100 ng/ml)." | 1.29 | P-glycoprotein expression in ovarian cancer cell line following treatment with cisplatin. ( Pagé, M; Yang, X, 1995) |
| "Etoposide efflux may have been inhibited, not because of (competitive) inhibition by BSO or disturbance of the energy required for this process, but probably because of plasma membrane alterations." | 1.28 | Modulation by D,L-buthionine-S,R-sulphoximine of etoposide cytotoxicity on human non-small cell lung, ovarian and breast carcinoma cell lines. ( Lafleur, MV; Lankelma, J; Mans, DR; Pinedo, HM; Retèl, J; Schuurhuis, GJ; Treskes, M, 1992) |
| "The sensitive/MDR human ovarian cancer cell line couple A2780/2780AD was used as a reference." | 1.28 | P-glycoprotein drug efflux pump involved in the mechanisms of intrinsic drug resistance in various colon cancer cell lines. Evidence for a saturation of active daunorubicin transport. ( Broxterman, HJ; Dekker, H; Lankelma, J; Schuurhuis, GJ; Spoelstra, EC, 1991) |
| "Verapamil was shown to be capable of increasing intracellular daunorubicin levels in normal lymphocytes isolated from patients undergoing chemotherapy for epithelial ovarian cancer." | 1.28 | Effect of verapamil on daunorubicin accumulation in lymphocytes isolated from patients undergoing chemotherapy. ( Crowther, D; Fox, BW; McGown, AT; Murphy, D, 1991) |
| " The fact that enhancement was 6-10 fold greater in resistant then in sensitive cells, as well as the loss of biphasic properties of adriamycin on dose-response curves after combined treatment, indicate that cepharanthine may play a role in overcoming drug resistance in some tumor cells." | 1.28 | Enhancement of adriamycin cytotoxicity in sensitive and resistant sublines of human tumor cells by calcium antagonists. ( Mircheva, J; Tsuruo, T, 1990) |
| "Verapamil was found to enhance the cytotoxic effect of vincristine against ovarian cancer cells." | 1.28 | [In vitro drug-resistance decrease of ovarian cancer cells]. ( Lu, SM, 1990) |
| "Verapamil, that was demonstrated previously to enhance the cell-killing activity of PE immunotoxins, enhanced the activity of several ricin A chain immunotoxins, including 454A12-rRTA, 260F9-rRTA, and 454C11-RTA." | 1.27 | Enhancement of the activity of immunotoxins made with either ricin A chain or Pseudomonas exotoxin in human ovarian and epidermoid carcinoma cell lines. ( FitzGerald, DJ; Pastan, I; Pirker, R; Willingham, MC, 1988) |
| "Eight patients with refractory ovarian cancer were treated on a pilot protocol of verapamil plus Adriamycin (Adria Laboratories, Columbus, OH)." | 1.27 | Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. ( Cunnion, RE; Hamilton, TC; Klecker, RW; Ostchega, Y; Ozols, RF; Parrillo, JE; Young, RC, 1987) |
| "Verapamil has been shown to reverse acquired drug resistance to Adriamycin (ADR) and vinblastine in the P388 leukemia and Ehrlich ascites carcinoma model systems." | 1.27 | Effect of verapamil on in vitro cytotoxicity of adriamycin and vinblastine in human tumor cells. ( Cox, TC; Crowley, J; Goodman, GE; Yen, YP, 1987) |
| " The steep dose-response relationships in other lines support the rationale for high-dose therapy either by intraperitoneal or systemic administration of drugs." | 1.27 | Pharmacologic reversal of drug resistance in ovarian cancer. ( Ozols, RF, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (21.67) | 18.7374 |
| 1990's | 31 (51.67) | 18.2507 |
| 2000's | 9 (15.00) | 29.6817 |
| 2010's | 5 (8.33) | 24.3611 |
| 2020's | 2 (3.33) | 2.80 |
| Authors | Studies |
|---|---|
| Sako, M | 1 |
| Suzuki, H | 1 |
| Yamamoto, N | 1 |
| Hirota, K | 1 |
| Silva, GL | 1 |
| Cui, B | 1 |
| Chávez, D | 1 |
| You, M | 1 |
| Chai, HB | 1 |
| Rasoanaivo, P | 1 |
| Lynn, SM | 1 |
| O'Neill, MJ | 1 |
| Lewis, JA | 1 |
| Besterman, JM | 1 |
| Monks, A | 2 |
| Farnsworth, NR | 1 |
| Cordell, GA | 1 |
| Pezzuto, JM | 1 |
| Kinghorn, AD | 1 |
| Wang, W | 1 |
| Wan, Q | 1 |
| Li, M | 2 |
| Qu, F | 1 |
| Liu, H | 1 |
| Chen, Y | 1 |
| Marker, SC | 1 |
| King, AP | 1 |
| Swanda, RV | 1 |
| Vaughn, B | 1 |
| Boros, E | 1 |
| Qian, SB | 1 |
| Wilson, JJ | 1 |
| Yang, CH | 1 |
| Wang, C | 1 |
| Ojima, I | 1 |
| Horwitz, SB | 1 |
| Zheng, W | 1 |
| Lin, Y | 1 |
| Zhan, X | 1 |
| Zhang, QH | 1 |
| Dou, HT | 1 |
| Xu, P | 1 |
| Zhuang, SC | 1 |
| Liu, PS | 1 |
| Vaidyanathan, A | 1 |
| Sawers, L | 1 |
| Gannon, AL | 1 |
| Chakravarty, P | 1 |
| Scott, AL | 1 |
| Bray, SE | 1 |
| Ferguson, MJ | 1 |
| Smith, G | 1 |
| Mertens-Walker, I | 1 |
| Bolitho, C | 1 |
| Baxter, RC | 1 |
| Marsh, DJ | 1 |
| Yu, T | 1 |
| Hu, K | 1 |
| Bai, J | 1 |
| Wang, Z | 1 |
| Violini, S | 1 |
| D'Ascenzo, S | 1 |
| Millimaggi, D | 1 |
| Miotti, S | 1 |
| Canevari, S | 1 |
| Pavan, A | 1 |
| Dolo, V | 1 |
| Szotek, PP | 1 |
| Pieretti-Vanmarcke, R | 1 |
| Masiakos, PT | 1 |
| Dinulescu, DM | 1 |
| Connolly, D | 1 |
| Foster, R | 1 |
| Dombkowski, D | 1 |
| Preffer, F | 1 |
| Maclaughlin, DT | 1 |
| Donahoe, PK | 1 |
| Zhanping, W | 1 |
| Xiaoyu, P | 1 |
| Na, C | 1 |
| Shenglan, W | 1 |
| Bo, W | 1 |
| Rogan, AM | 1 |
| Hamilton, TC | 5 |
| Young, RC | 4 |
| Klecker, RW | 2 |
| Ozols, RF | 6 |
| Yano, S | 1 |
| Sone, S | 1 |
| Nishioka, Y | 1 |
| Naito, M | 1 |
| Tsuruo, T | 2 |
| Ogura, T | 1 |
| Alvarez, M | 1 |
| Paull, K | 1 |
| Hose, C | 1 |
| Lee, JS | 1 |
| Weinstein, J | 1 |
| Grever, M | 1 |
| Bates, S | 1 |
| Fojo, T | 1 |
| Spoelstra, EC | 3 |
| Westerhoff, HV | 2 |
| Pinedo, HM | 5 |
| Dekker, H | 3 |
| Lankelma, J | 8 |
| Guiral, M | 1 |
| Viratelle, O | 1 |
| Smellie, M | 1 |
| Kelland, LR | 3 |
| Thurston, DE | 1 |
| Souhami, RL | 1 |
| Hartley, JA | 1 |
| Sharp, SY | 1 |
| Rowlands, MG | 1 |
| Jarman, M | 1 |
| Plumb, JA | 1 |
| Wishart, GC | 1 |
| Setanoians, A | 1 |
| Morrison, JG | 1 |
| Hamilton, T | 1 |
| Bicknell, SR | 1 |
| Kaye, SB | 1 |
| Parekh, H | 1 |
| Simpkins, H | 1 |
| Aherne, GW | 1 |
| Hardcastle, A | 1 |
| Valenti, M | 1 |
| Bryant, A | 1 |
| Rogers, P | 1 |
| Pettit, GR | 1 |
| Srirangam, JK | 1 |
| Yang, X | 1 |
| Pagé, M | 1 |
| Elsinga, PH | 1 |
| Franssen, EJ | 1 |
| Hendrikse, NH | 1 |
| Fluks, L | 1 |
| Weemaes, AM | 1 |
| van der Graaf, WT | 1 |
| de Vries, EG | 1 |
| Visser, GM | 1 |
| Vaalburg, W | 1 |
| Harstrick, A | 1 |
| Vanhoefer, U | 2 |
| Schleucher, N | 1 |
| Schroeder, J | 1 |
| Baumgart, J | 1 |
| Scheulen, ME | 1 |
| Wilke, H | 1 |
| Seeber, S | 1 |
| Smeets, M | 1 |
| Raymakers, R | 1 |
| Vierwinden, G | 1 |
| Pennings, A | 1 |
| van de Locht, L | 1 |
| Wessels, H | 1 |
| Boezeman, J | 1 |
| de Witte, T | 1 |
| Gornati, D | 1 |
| Zaffaroni, N | 1 |
| Villa, R | 1 |
| De Marco, C | 1 |
| Silvestrini, R | 1 |
| Yin, MB | 1 |
| Guo, B | 1 |
| Voigt, W | 1 |
| Gibbs, JF | 1 |
| Skenderis, BS | 1 |
| Frank, C | 1 |
| Wrzosek, C | 1 |
| Rustum, YM | 1 |
| Choi, SU | 1 |
| Park, SH | 1 |
| Kim, KH | 1 |
| Choi, EJ | 1 |
| Kim, S | 1 |
| Park, WK | 1 |
| Zhang, YH | 1 |
| Kim, HS | 1 |
| Jung, NP | 1 |
| Lee, CO | 1 |
| Posypanova, GA | 1 |
| Shmyrev, II | 1 |
| Rodina, AV | 1 |
| Muizhnek, EL | 1 |
| Severin, ES | 1 |
| Luzhkov, YM | 1 |
| Severin, SE | 1 |
| Duan, Z | 1 |
| Feller, AJ | 1 |
| Penson, RT | 1 |
| Chabner, BA | 1 |
| Seiden, MV | 1 |
| Schuldes, H | 1 |
| Dolderer, JH | 1 |
| Zimmer, G | 1 |
| Knobloch, J | 1 |
| Bickeböller, R | 1 |
| Jonas, D | 1 |
| Woodcock, BG | 1 |
| Meng, J | 1 |
| You, Z | 1 |
| Guo, Y | 1 |
| Liao, M | 1 |
| Chen, H | 2 |
| Shui, H | 1 |
| Alfonso-De Matte, MY | 1 |
| Moses-Soto, H | 1 |
| Kruk, PA | 1 |
| Aird, RE | 1 |
| Cummings, J | 1 |
| Ritchie, AA | 1 |
| Muir, M | 1 |
| Morris, RE | 1 |
| Sadler, PJ | 1 |
| Jodrell, DI | 1 |
| Mans, DR | 1 |
| Schuurhuis, GJ | 5 |
| Treskes, M | 1 |
| Lafleur, MV | 1 |
| Retèl, J | 1 |
| Wasserman, L | 1 |
| Aviram, R | 1 |
| Levavi, H | 1 |
| Ovadia, J | 1 |
| Shneyuor, Y | 1 |
| Frisch, A | 1 |
| Blau, O | 1 |
| Beery, E | 1 |
| Novogrodsky, A | 1 |
| Nordenberg, J | 1 |
| Mutch, DG | 1 |
| Herzog, TJ | 1 |
| Chen, CA | 1 |
| Collins, JL | 1 |
| Broxterman, HJ | 5 |
| Mizuno, K | 1 |
| Furuhashi, Y | 1 |
| Maeda, O | 1 |
| Iwata, M | 1 |
| Misawa, T | 1 |
| Kawai, M | 1 |
| Kano, T | 1 |
| Tomoda, Y | 1 |
| McGown, AT | 1 |
| Murphy, D | 1 |
| Crowther, D | 1 |
| Fox, BW | 1 |
| Hendrick, AM | 1 |
| Harris, AL | 1 |
| Cantwell, BM | 1 |
| Mircheva, J | 1 |
| Lu, SM | 1 |
| Assaraf, YG | 1 |
| Molina, A | 1 |
| Schimke, RT | 1 |
| Bénard, J | 1 |
| Da Silva, J | 1 |
| Teyssier, JR | 1 |
| Riou, G | 1 |
| Pirker, R | 2 |
| FitzGerald, DJ | 2 |
| Willingham, MC | 2 |
| Pastan, I | 2 |
| Fojo, A | 1 |
| Kuiper, CM | 1 |
| Kaptein, LC | 1 |
| van der Hoeven, JJ | 1 |
| Cunnion, RE | 1 |
| Ostchega, Y | 1 |
| Parrillo, JE | 1 |
| Goodman, GE | 1 |
| Yen, YP | 1 |
| Cox, TC | 1 |
| Crowley, J | 1 |
| Gibby, EM | 1 |
| Boyse, O | 1 |
| Hill, BT | 1 |
1 review available for verapamil and Cancer of Ovary
| Article | Year |
|---|---|
Multidrug resistance in ovarian cancer.
Topics: DNA Repair; Doxorubicin; Drug Resistance; Female; Gene Amplification; Glutathione; Humans; Ovarian N | 1987 |
2 trials available for verapamil and Cancer of Ovary
| Article | Year |
|---|---|
Reversal of adriamycin resistance by verapamil in human ovarian cancer.
Topics: Cell Line; Clinical Trials as Topic; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance; | 1984 |
Verapamil with mitoxantrone for advanced ovarian cancer: a negative phase II trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Feasibility Studies; Female; | 1991 |
57 other studies available for verapamil and Cancer of Ovary
| Article | Year |
|---|---|
Highly increased cellular accumulation of vincristine, a useful hydrophobic antitumor-drug, in multidrug-resistant solid cancer cells induced by a simply reduced taxinine.
Topics: Antineoplastic Agents, Phytogenic; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synerg | 1999 |
Modulation of the multidrug-resistance phenotype by new tropane alkaloid aromatic esters from Erythroxylum pervillei.
Topics: Alkaloids; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; Crystal | 2001 |
Design, synthesis and biological evaluation of seco-DSP/DCK derivatives reversing P-glycoprotein-mediated paclitaxel resistance in A2780/T cells.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transport | 2023 |
Exploring Ovarian Cancer Cell Resistance to Rhenium Anticancer Complexes.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Cell Line, Tumor; Coordination | 2020 |
Taxol Analogues Exhibit Differential Effects on Photoaffinity Labeling of β-Tubulin and the Multidrug Resistance Associated P-Glycoprotein.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Drug Resistance, Multiple; Drug Resistance, | 2018 |
Encapsulation of verapamil and doxorubicin by MPEG-PLA to reverse drug resistance in ovarian cancer.
Topics: Animals; Cell Line; Cell Line, Tumor; Cell Survival; Doxorubicin; Drug Carriers; Drug Delivery Syste | 2018 |
Tumor recurrence and drug resistance properties of side population cells in high grade ovary cancer.
Topics: Antigens, CD; Antigens, Neoplasm; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Bindi | 2015 |
ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells.
Topics: Acridines; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Blotting, Western; | 2016 |
Gonadotropin-induced ovarian cancer cell migration and proliferation require extracellular signal-regulated kinase 1/2 activation regulated by calcium and protein kinase C{delta}.
Topics: Acetophenones; Benzopyrans; Calcium; Calcium Channels, L-Type; Cell Line, Tumor; Cell Movement; Cell | 2010 |
Reversal of adriamycin resistance in ovarian carcinoma cell line by combination of verapamil and low-level ultrasound.
Topics: Antineoplastic Agents; Cell Survival; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Intrac | 2003 |
Induction of a multifactorial resistance phenotype by high paclitaxel selective pressure in a human ovarian carcinoma cell line.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Div | 2004 |
Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness.
Topics: Animals; Anti-Mullerian Hormone; Antineoplastic Agents; Benzimidazoles; Cell Line, Tumor; CHO Cells; | 2006 |
Voltage-gated K+ channels are associated with cell proliferation and cell cycle of ovarian cancer cell.
Topics: 4-Aminopyridine; Calcium; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Female; Humans; Ovari | 2007 |
Cyclosporin A enhances susceptibility of multi-drug resistant human cancer cells to anti-P-glycoprotein antibody-dependent cytotoxicity of monocytes, but not of lymphocytes.
Topics: Antibodies, Monoclonal; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; ATP Binding Cas | 1994 |
Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line; Cell Surv | 1995 |
The multidrug-resistance-reverser verapamil interferes with cellular P-glycoprotein-mediated pumping of daunorubicin as a non-competing substrate.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport, Active; Carcinoma, No | 1994 |
Cooperative P-glycoprotein mediated daunorubicin transport into DNA-loaded plasma membrane vesicles.
Topics: Adenosine Triphosphate; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transpor | 1994 |
Cellular pharmacology of novel C8-linked anthramycin-based sequence-selective DNA minor groove cross-linking agents.
Topics: Anthramycin; Antibiotics, Antineoplastic; Benzodiazepines; Cross-Linking Reagents; DNA Damage; DNA, | 1994 |
Effects of a new antioestrogen, idoxifene, on cisplatin- and doxorubicin-sensitive and -resistant human ovarian carcinoma cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Calmodulin; Cisplatin; Doxorubicin; Drug Resistance; | 1994 |
Identification of a multidrug resistance modulator with clinical potential by analysis of synergistic activity in vitro, toxicity in vivo and growth delay in a solid human tumour xenograft.
Topics: Animals; Calcium Channel Blockers; Doxorubicin; Drug Resistance; Drug Synergism; Epirubicin; Female; | 1994 |
Cross-resistance and collateral sensitivity to natural product drugs in cisplatin-sensitive and -resistant rat lymphoma and human ovarian carcinoma cells.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Buthionine | 1996 |
Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay.
Topics: Animals; Antineoplastic Agents; Carcinoma; Cell Division; Colonic Neoplasms; Cross Reactions; Depsip | 1996 |
P-glycoprotein expression in ovarian cancer cell line following treatment with cisplatin.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cisplatin; Doxorubic | 1995 |
Carbon-11-labeled daunorubicin and verapamil for probing P-glycoprotein in tumors with PET.
Topics: Animals; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carbo | 1996 |
Activity of N-benzyl-adriamycin-14-valerate (AD198), a new anthracycline derivate, in multidrug resistant human ovarian and breast carcinoma cell lines.
Topics: Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplas | 1995 |
A low but functionally significant MDR1 expression protects primitive haemopoietic progenitor cells from anthracycline toxicity.
Topics: Antigens, CD34; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Southern; Cell Di | 1997 |
Modulation of melphalan and cisplatin cytotoxicity in human ovarian cancer cells resistant to alkylating drugs.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Blotting, Northern; Calcium Channel Blocke | 1997 |
Novel cellular determinants for reversal of multidrug resistance in cells expressing P170-glycoprotein.
Topics: Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Calcium Channe | 1998 |
The bisbenzylisoquinoline alkaloids, tetrandine and fangchinoline, enhance the cytotoxicity of multidrug resistance-related drugs via modulation of P-glycoprotein.
Topics: Alkaloids; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member | 1998 |
Alpha-fetoprotein-mediated targeting--a new strategy to overcome multidrug resistance of tumour cells in vitro.
Topics: alpha-Fetoproteins; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Memb | 1997 |
Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype.
Topics: Breast Neoplasms; Chemokine CCL2; DNA, Complementary; Doxorubicin; Drug Resistance, Multiple; Female | 1999 |
Reversal of multidrug resistance and increase in plasma membrane fluidity in CHO cells with R-verapamil and bile salts.
Topics: Animals; Antineoplastic Agents; Cell Division; CHO Cells; Cisplatin; Cricetinae; Cricetulus; Doxorub | 2001 |
[Effects of estradiol and medroxyprogesterone on the growth and doxorubin-resistance of drug-resistant human epithelial ovarian cancer cell line OVCAR-3].
Topics: Cell Division; Doxorubicin; Drug Resistance, Neoplasm; Estradiol; Female; Genes, MDR; Humans; Medrox | 1999 |
[Apoptosis induced by cisplatin and verapamil or SDZ PSC 833 in human ovarian cell lines].
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Line, Tumor; Cisplatin; | 2000 |
Calcium-mediated telomerase activity in ovarian epithelial cells.
Topics: Cadmium; Calcium; Cell Transformation, Neoplastic; Cells, Cultured; Chromium; Epithelial Cells; Fema | 2002 |
In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; ATP Binding Cassette Transporter, S | 2002 |
Modulation by D,L-buthionine-S,R-sulphoximine of etoposide cytotoxicity on human non-small cell lung, ovarian and breast carcinoma cell lines.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Buthionine Sulfoximine; Carcinoma, Non-Small-Cell | 1992 |
A cell line with unusual characteristics from an ovarian carcinoma patient: modulation of sensitivity to antitumour drugs.
Topics: Adenocarcinoma; Antigens, Neoplasm; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfami | 1992 |
The effects of cyclosporin A on the lysis of ovarian cancer cells by cisplatin or adriamycin.
Topics: Antimetabolites, Antineoplastic; Buthionine Sulfoximine; Cell Death; Cisplatin; Cycloheximide; Cyclo | 1992 |
P-glycoprotein drug efflux pump involved in the mechanisms of intrinsic drug resistance in various colon cancer cell lines. Evidence for a saturation of active daunorubicin transport.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding Sites; Biological Transpor | 1991 |
Mitomycin C cross-resistance induced by adriamycin in human ovarian cancer cells in vitro.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporins; Cystadenocarcinoma; DNA, Neop | 1990 |
Evidence for daunomycin efflux from multidrug-resistant 2780AD human ovarian carcinoma cells against a concentration gradient.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport, Active; Daunorubicin; | 1990 |
Effect of verapamil on daunorubicin accumulation in lymphocytes isolated from patients undergoing chemotherapy.
Topics: Daunorubicin; Epithelium; Female; Humans; Lymphocytes; Ovarian Neoplasms; Time Factors; Verapamil | 1991 |
Enhancement of adriamycin cytotoxicity in sensitive and resistant sublines of human tumor cells by calcium antagonists.
Topics: Alkaloids; Benzylisoquinolines; Calcium Channel Blockers; Dose-Response Relationship, Drug; Doxorubi | 1990 |
[In vitro drug-resistance decrease of ovarian cancer cells].
Topics: Cisplatin; Cystadenocarcinoma; Drug Resistance; Drug Screening Assays, Antitumor; Drug Synergism; Fe | 1990 |
Cyclosporin A and verapamil have different effects on energy metabolism in multidrug-resistant tumour cells.
Topics: Adenosine Monophosphate; Adenosine Triphosphate; Cell Line; Cyclosporins; Daunorubicin; Drug Resista | 1990 |
Cross-resistance to the lipid-soluble antifolate trimetrexate in human carcinoma cells with the multidrug-resistant phenotype.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cell Line; Drug Resistance; Female; Gen | 1989 |
Over-expression of MDR1 gene with no DNA amplification in a multiple-drug-resistant human ovarian carcinoma cell line.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Chromosome Deletion; Dactinomycin; Doxorubicin; Drug | 1989 |
Anti-transferrin receptor antibody linked to Pseudomonas exotoxin as a model immunotoxin in human ovarian carcinoma cell lines.
Topics: ADP Ribose Transferases; Bacterial Toxins; Breast Neoplasms; Cell Line; Cell Survival; Colony-Formin | 1985 |
Enhancement of the activity of immunotoxins made with either ricin A chain or Pseudomonas exotoxin in human ovarian and epidermoid carcinoma cell lines.
Topics: ADP Ribose Transferases; Bacterial Toxins; Cadaverine; Calmodulin; Carcinoma, Squamous Cell; Cell Li | 1988 |
Induction by verapamil of a rapid increase in ATP consumption in multidrug-resistant tumor cells.
Topics: Adenosine Triphosphate; Animals; Daunorubicin; Drug Resistance; Female; Humans; Hydrolysis; Osmolar | 1988 |
Potentiation of doxorubicin cytotoxicity by the calcium antagonist bepridil in anthracycline-resistant and -sensitive cell lines. A comparison with verapamil.
Topics: Bepridil; Calcium Channel Blockers; Calmodulin; Cell Line; Doxorubicin; Drug Resistance; Drug Synerg | 1987 |
Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Doxorubicin; Drug Resistance; Female | 1987 |
Effect of verapamil on in vitro cytotoxicity of adriamycin and vinblastine in human tumor cells.
Topics: Breast Neoplasms; Cell Survival; Clone Cells; Colonic Neoplasms; Doxorubicin; Drug Resistance; Esoph | 1987 |
Selective interactions of verapamil with anthraquinones in adriamycin-sensitive and -resistant murine and human tumour cell lines in vitro.
Topics: Cell Survival; Colony-Forming Units Assay; Doxorubicin; Drug Interactions; Female; Humans; Mitoxantr | 1987 |
Modulation of drug resistance in human ovarian cancer: experimental results and clinical applications.
Topics: Animals; Buthionine Sulfoximine; Cell Line; Doxorubicin; Drug Resistance; Drug Synergism; Female; Gl | 1986 |
Pharmacologic reversal of drug resistance in ovarian cancer.
Topics: Antineoplastic Agents; Cell Line; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Drug Res | 1985 |